Banner
HomeBest Practices → Amgen Cuts Repatha's Price 60% as Scrutiny of Drug Costs Heats Up

Amgen Cuts Repatha's Price 60% as Scrutiny of Drug Costs Heats Up Print E-mail
Written by FHI's Week in Review   
Monday, 29 October 2018 11:03
 
Patrice Wendling reports for Medscape on October 24, 2018:
 
Amgen announced today it is lowering the cost of its cholesterol-lowering drug, evolocumab ( Repatha), by roughly 60%. The move was designed to increase demand by lowering out-of-pocket costs, especially for Medicare patients, who currently pay between $280 and $370 a month in out-of-pocket costs, but will now pay $25 to $150 a month, Amgen officials said in a telephone press briefing.
 
Read more in the current issue of Week in Review>> https://conta.cc/2Q4gG8g
 
Last Updated on Monday, 29 October 2018 11:11
 


Banner
Website design, development, and hosting provided by
Netphiles